Medication among patients with type 1 diabetes and predialytic renal disease

Abstract

AimsTo examine use and changes of medication in the three years before start of chronic renal replacement therapy (RRT) among patients with type 1 diabetes, and the association between predialytic medication and survival on RRT. MethodsWe recorded medication of 496 patients with type 1 diabetes before and after start of RRT in 2000–2006 and followed up until death or end of 2009. Data were retrieved from the Finnish Registry for Kidney Diseases and from the FinDM diabetes database. We evaluated the use of renin–angiotensin system (RAS) blockers, calcium channel blockers, β-blockers, statins, vitamin D, erythropoiesis-stimulating agents, and phosphate binders over three years. The association between predialytic medication and survival was assessed using Cox proportional hazards regression. ResultsMedication increased markedly with progressing renal insufficiency. Almost 70% of the patients used calcium channel blockers and β-blockers before initiating RRT. Use of calcium channel blockers (RR 0.72, 95% CI 0.53–0.95) and vitamin D (RR 0.70, 95% CI 0.52–0.94) at start of RRT were associated with better survival when adjusted for age and sex, but after further adjustment the association lost statistical significance. ConclusionsAmong type 1 diabetes patients in the predialysis phase, use of medication is abundant. Use of medication appears to keep patients at an equal survival level to those without the same medication. However, due to the observational nature of our study, conclusions regarding the effect of medication on survival must be made with caution.